All News

April Armstrong, MD, discussed the latest data on apremilast, deucravacitinib, and emerging TYK2 and IL-23 inhibitors at Midwinter Hawaii.

The dermatologic tips offered in this short slide show come from 4 renowned professionals and reflect their subspecialties.

Anila Chadha, MD, highlights key preventive strategies to reduce CVD risk in patients with obesity and how to tailor them to address individual patient needs.

Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.

An FDA decision on GSK's Shingrix application is expected by June 20, 2025.

After sometimes heated exchanges during confirmation hearings, the Senate vote was 52-48 in favor of RFK, Jr, with Sen Mitch McConnel the sole opposing Republican.

The 2 analyses of data on fertility and infant mortality were conducted in the first 14 states to impose complete or 6-week bans after the Dobbs decision in June 2022.

Your daily dose of the clinical news you may have missed.

The 2025 Winter Clinical Hawaii kicks off today with the first full day of educational sessions starting tomorrow, February 15 - here's what to look for.

The Winter Clinical Hawaii Dermatology Conference will kick off on the Big Island on February 14th. Check out the agenda and the option to attend virtually.

Your daily dose of the clinical news you may have missed.

AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.

AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.

In a randomized clinical trial, omalizumab achieved a 36% treatment success rate for multi-food allergy compared with 19% for oral immunotherapy.

Some hospitals have EDs filled with patients and a number of states are reporting the 2024-2025 version of a COVID-19, flu, and RSV tripledemic.

AAAAI 2025. Treatment response rates with daily use of the VIASKIN peanut patch increased from 39% at baseline to 73.3% at 60 months in youth aged 4 to 11 years.

Your daily dose of the clinical news you may have missed.

Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.